{"id":108017,"date":"2020-06-01T13:02:54","date_gmt":"2020-06-01T20:02:54","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/06\/eli-lilly-and-abcellera-dose-first-patients-with-covid-19-antibody-in-phase-i-study"},"modified":"2020-06-01T13:02:54","modified_gmt":"2020-06-01T20:02:54","slug":"eli-lilly-and-abcellera-dose-first-patients-with-covid-19-antibody-in-phase-i-study","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/06\/eli-lilly-and-abcellera-dose-first-patients-with-covid-19-antibody-in-phase-i-study","title":{"rendered":"Eli Lilly and AbCellera Dose First Patients with COVID-19 Antibody in Phase I Study"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/eli-lilly-and-abcellera-dose-first-patients-with-covid-19-antibody-in-phase-i-study.jpg\"><\/a><\/p>\n<p><strong><a href=\"https:\/\/www.biospace.com\/employer\/395010\/eli-lilly-and-company\/\">Eli Lilly<\/a><\/strong> and <strong><a href=\"https:\/\/www.biospace.com\/employer\/543022\/abcellera-biologics-inc-\/\">AbCellera<\/a> <\/strong>dosed the first patients in a Phase I study of a <strong><a href=\"https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-begins-worlds-first-study-potential-covid-19-antibody\">potential antibody treatment<\/a><\/strong> for COVID-19. The two companies were able to get their antibody candidate into the clinic within two months of announcing their <strong><a href=\"https:\/\/www.biospace.com\/article\/abcellera-and-eli-lilly-team-up-to-develop-antibodies-for-coronavirus-treatment\/\">collaboration<\/a><\/strong> in response to the global pandemic.<\/p>\n<p>The announcement was made a day after it was announced that more than 6 million people across the globe have been infected with the virus, including 1.79 million in the United States. COVID-19 has been responsible for the deaths of more than 372,000 people, with nearly one-third (104,383) in the U.S.<\/p>\n<p>Patients were dosed with LY-CoV555, a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, which should neutralize the virus, and potentially prevent and treat COVID-19. Because it\u2019s an antibody derived from the blood of a recovered patient, Eli Lilly said LY-CoV555 is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19. The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic. The announcement was made a day after it was [\u2026]<\/p>\n","protected":false},"author":575,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-108017","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/108017","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/575"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=108017"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/108017\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=108017"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=108017"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=108017"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}